Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
GB002, a Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the SU5416 Hypoxia Rat Model of PAH
